Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection

Clinical Infectious Diseases

Volumn 50, Issue 7, 2010, Pages 963-969

  Ling, Li M ^a   Chow, Angela L ^b   Lye, David C ^a   Tan, Adriana S ^b   Krishnan, Prabha ^a   Cui, Lin ^a   Win, Nwe N ^b   Chan, Monica ^a   Lim, Poh L ^a   Lee, Cheng C ^a   Leo, Yee S ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b Clinical Epidemiology   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR;

ADULT; ARTICLE; CLINICAL FEATURE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; COUGHING; DISEASE DURATION; DRUG EFFECT; FEMALE; FEVER; FLU LIKE SYNDROME; HOSPITAL ADMISSION; HUMAN; IMMUNOCOMPETENCE; INFLUENZA; INFLUENZA VIRUS A H1N1; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OXYGEN SATURATION; PANDEMIC; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RHINORRHEA; SORE THROAT; THROAT CULTURE; TREATMENT DURATION; VIRUS CULTURE; VIRUS SHEDDING;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DISEASE OUTBREAKS; FEMALE; FEVER; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; OSELTAMIVIR; SINGAPORE; STATISTICS, NONPARAMETRIC; VIRUS SHEDDING; YOUNG ADULT;

EID: 77749308310     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/651083     Document Type: Article

References (30)

1. New influenza A (H1N1) virus infections: global surveillance summary, May 2009. World Health Organization. Weekly Epidemiological Record 2009; 84: 173-184. http://www.who.int/wer/2009/wer8420/en/index.html. Accessed 5 June 2009.
2. World Health Organization (WHO). Pandemic (H1N1) 2009-update 70. http://www.who.int/csr/don/2009-10-16/en/index.html. Accessed 23 October 2009.
3. Centers for Disease Control and Prevention. Update: Influenza Activity-United States, April-August 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 1009-1012.
4. Centers for Disease Control and Prevention. Surveillance for the 2009 pandemic influenza A (H1N1) virus and seasonal influenza virusesNew Zealand, 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 918-921.
5. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361: 1935-1944.
6. Centers for Disease Control and Prevention. Surveillance for pediatric deaths associated with 2009 pandemic influenza A (H1N1) virus infection-United States, April-August 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 941-947.
7. Dominguez-Cherit G, Lapinsky SE, Macias AE, et al. Critically ill patients with 2009 influenza A (H1N1) in Mexico. JAMA 2009; 302(17): 1880-1887.
8. The ANZIC influenza investigators. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 2009; 361(20): 1925-1934.
9. Jamieson DJ, Honein MA, Rasmussen SA, et al. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet 2009; 374: 451-458.
10. Charlier C, Enouf V, Lanternier F, et al. Kinetics of nasopharyngeal shedding of novel H1N1 (swine-like) influenza A virus in an immunocompetent adult under oseltamivir therapy. Clin Microbiol Infect 2009; 15(12): 1189-1191.
11. Taqman(R) Gene Expression, http://www.ncbi.nlm.nih.gov/projects/genome/ probe/doc/ProjTaqMan.shtml. Accessed 26 October 2009.
12. Ziegler T, Hall H, Sanchez-Fauquier A, Gamble WC, Cox NJ. Typeand subtype-specific detection of influenza viruses in clinical specimens by rapid culture assay. J Clin Microbiol 1995; 33: 318-321.
13. LIGHT DIAGNOSTICS(TM) Influenza A & B DFA kit. http://www.millipore. com/catalogue/item/3123. Accessed 26 October 2009.
14. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalised with influenza. J Infect Dis 2009; 200: 492-500.
15. 15. Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003; 326: 1235. (Pubitemid 36688077)
16. 16. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomised controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283: 1016-1024. (Pubitemid 30112215)
17. 17. Boivin G, Coulombe Z, Wat C. Quantification of the influenza virus load by real-time polymerase chain reaction in nasopharyngeal swabs of patients treated with oseltamivir. J Infect Dis 2003; 188: 578-580. (Pubitemid 37011811)
18. Carrat F, Vergu E, Ferguson NM, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 2008; 167: 775-785.
19. Nicholson KG, Wood JM, Zambon M. Influenza. Lancet 2003; 362: 1733-1745.
20. Cox NJ, Subbarao K. Influenza. Lancet 1999; 354: 1277-1282.
21. Lye DC, Ang BS, Leo YS. Review of human infections with avian influenza H5N1 and proposed local clinical management guideline. Ann Acad Med Singapore 2007; 36: 285-292.
22. 22. Leekha S, Zitterkopf NL, Espy MJ, Smith TF, Thompson RL, Sampathkumar P. Duration of influenza A virus shedding in hospitalised patients and implications for infection control. Infect Control Hosp Epidemiol 2007; 28: 1071-1076. (Pubitemid 47345268)
23. De Serres G, Rouleau I, Hamelin ME, et al. Shedding of novel 2009 pandemic H1N1 (nH1N1) virus at one week post illness onset. In: Program and abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. 2009. Abstract K-1918a.
24. Witkop CT, Duffy MR, Macias EA, et al. Novel influenza A (H1N1) outbreak at the U.S. Air Force Academy: epidemiology and viral shedding duration. Am J Prev Med 2010; 38(2): 121-126.
25. Influenza pandemic (H1N1) 2009 (68): Vietnam, virus clearance, http://www.promedmail.org/pls/otn/f?p=2400:1001:3582407762160094::NO: :F2400-P1001-BACK-PAGE,F2400-P1001-PUB-MAIL-ID: 1010, 79587. Accessed 23 October 2009.
26. 26. Boivin G, Goyette N, Hardy I, Aoki F, Wagner A, Trottier S. Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults. J Infect Dis 2000; 181: 1471-1474. (Pubitemid 30252558)
27. 27. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl J Med 1997; 337: 874-880. (Pubitemid 27408569)
28. 28. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355: 1845-1850. (Pubitemid 30311875)
29. Johnson DF, Druce JD, Birch C, Grayson ML. A quantitative assessment of" the efficacy of surgical and N95 masks to filter influenza virus in patients with acute influenza infection. Clin Infect Dis 2009; 49: 275-277.
30. Grayson ML, Melvani S, Druce J, et al. Efficacy of soap and water and alcohol-based hand-rub preparations against live H1N1 influenza virus on the hands of human volunteers. Clin Infect Dis 2009; 48: 285-291.